Observational studyThoracic cancer2025
An Innovative Management in the Diagnosis of Mediastinal Masses.
Observational study in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of giant thymolipoma: case report.AME case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe mediastinum is a complex anatomical region that contains vital structures such as the great vessels, heart, esophagus, and trachea. Mediastinal masses include a wide range of lesions, both malignant and benign. Our study aimed to evaluate whether the combination of intraoperative ultrasound (IUS) and VATS can allow obtaining an adequate, correct, and safer diagnosis in patients with a mediastinal mass, especially in severely ill patients affected by heart failure, renal failure, advanced oncological stage, and respiratory failure. MATERIAL AND
methodThis single-center, retrospective, observational study included 298 consecutive patients with mediastinal mass, evaluated between March 2018 and December 2024 at the Thoracic Surgery Department of Vanvitelli University of Naples. All patients underwent biopsies of mediastinal masses via VATS with IUS. Mediastinal masses were classified based on their ultrasound characteristics, allowing precise identification of the site and solid part of the lesions for biopsy. No significant complications were reported.
resultsA total of 298 patients underwent VATS for mediastinal mass biopsy. About 185 of these patients underwent biopsies via VATS with IUS. All were under general anesthesia with single-lung ventilation. A specific diagnosis was obtained in all patients who underwent biopsies via VATS with IUS (185/185), with lymphoma being the most common entity (58.6%), followed by germ cell tumors (24.3%) and thymic carcinoma (12.4%). A significant difference in diagnostic accuracy, specificity, and sensibility was found between the group that used IUS versus the group in which no IUS was used (100%vs. 93%, 99.8% vs. 94%, 98.5% vs. 90.5% respect).
conclusionIUS-guided biopsy allows for correct, safe, and precise identification of mediastinal lesions, establishing IUS as the "Gold Standard" for procedure guidance when the target lesion is adequately visualized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.